UC Davis Comprehensive Cancer Center | Strategic Alliance Partners

R. Lor Randall, MD, FACS, reviews the prognostic potential and current clinical limitations of personalized ctDNA panels in osteosarcoma.

R. Lor Randall, MD, FACS, discusses how ctDNA could be used to identify microscopic residual disease in patients who appear radiographically disease-free.

R. Lor Randall, MD, FACS, discusses how tumor-informed ctDNA sequencing can identify osteosarcoma relapse months before radiographic detection.

R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.

R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.

R. Lor Randall, MD, FACS, discusses how the introduction of systemic therapies such as pimicotinib in TGCT enables a tumor biology–informed approach to care.

R. Lor Randall, MD, FACS, discusses the rationale of a meta-analysis comparing IM nailing and EP reconstruction for patients with bone metastases.

R. Lor Randall, MD, FACS, highlights a recent meta-analysis comparing 2 approaches to surgical management for patients with femoral metastases.

R. Lor Randall, MD, FACS, discusses how the BOOM consensus provides a global standard for managing complex infections in orthopedic oncology.

R. Lor Randall, MD, FACS, discusses global consensus on managing periprosthetic joint infections in sarcoma and complex bone reconstructions.

R. Lor Randall, MD, FACS, highlights primary objectives of, and key takeaways from, the BOOM consensus meeting on PJI management in orthopedic oncology.

R. Lor Randall, MD, FACS, discusses the clinical utility and global variability of DAIR procedures for periprosthetic joint infection in sarcoma.

R. Lor Randall, MD, FACS, discusses results from an analysis of factors associated with local recurrence risk in nonmetastatic Ewing sarcoma.

R. Lor Randall, MD, FACS, discusses a report on factors predicting local recurrence in nonmetastatic Ewing sarcoma from the phase 3 AEWS1031 trial.

R. Lor Randall, MD, FACS, discusses global variation in DAIR strategies for post–limb salvage infections, highlighting needs for standardization and multidisciplinary coordination.

UC Davis Health joins an elite group recognized for top-tier pancreatic cancer care and research.

Patient who are adolescent or young adults are at higher risk of metastatic recurrence according to researchers at UC Davis Health.

R. Lor Randall, MD, FACS, discusses findings from a phase 2 study of denosumab in patients with osteosarcoma.

R. Lor Randall, MD, FACS, discusses the multidisciplinary nature of research aiming to develop a predictive model of sarcoma survivorship.

R. Lor Randall, MD, FACS, discusses the potential implications of research into how socioeconomic disparities and cancer biology impact long-term outcomes in pediatric sarcoma.

R. Lor Randall, MD, FACS, outlines the aims and phases of a prospective study evaluating outcome disparities in pediatric sarcoma survivorship care.

R. Lor Randall, MD, discusses the need to move beyond modest survival improvements in pediatric bone sarcoma toward equitable, precision survivorship care.

Experts highlight pivotal data in EGFR- and HER2-mutant NSCLC from the 2025 ESMO Congress, including updates on ADCs, TKIs, and real-world outcomes in LMD.

R. Lor Randall, MD, FACS, discusses a new STS surveillance algorithm based on findings that show the comparable diagnostic utility of ultrasound and MRI.

R. Lor Randall, MD, FACS, summarizes the current status of and future directions for imaging protocols for post-surgical extremity STS surveillance.

R. Lor Randall, MD, FACS, compares the diagnostic accuracy, recurrence detection rates, and cost effectiveness of MRI vs ultrasound STS surveillance.

Targeted gene therapy kills herpesvirus-linked cancer cells, sparing healthy tissue

R. Lor Randall, MD, FACS, discusses the current paradigm and future trajectory of imaging modalities for the surveillance of soft tissue sarcoma.

Ultrasound is cheaper, faster, and is widely available compared with MRI, but is it enough to displace the gold standard imaging tool?